Skip to main content

Gene Mutations

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Inozyme Pharma
Inozyme PharmaMA - Boston
1 program
1
INZ-701Phase 21 trial
Active Trials
NCT06462547Recruiting200Est. Dec 2030

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
Inozyme PharmaINZ-701

Clinical Trials (1)

Total enrollment: 200 patients across 1 trials

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

Start: Jun 2024Est. completion: Dec 2030200 patients
Phase 2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 200 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.